Overview
- The Broad Institute, Boston Children’s Hospital and The Jackson Laboratory announced the formation of the nonprofit Center for Therapeutic Genetics to turn recent gene‑editing advances into repeatable clinical procedures.
- The center is in a founding phase and is not yet treating patients or accepting referrals while it builds platforms for methods, safety data, manufacturing and clinician training.
- CTG’s initial work will prioritize precision gene‑editing programs for rare pediatric epilepsies with support from ARPA‑H funding tied to the agency’s THRIVE effort.
- Founders say CTG will move beyond one‑off N=1 experiments by creating programmable, modular approaches using CRISPR, base editing and prime editing that can be adapted across rare diseases.
- Leaders expect the nonprofit, funded philanthropically and publicly, to lower costs and widen access for families who now must fund bespoke therapies, and to create shared infrastructure that could speed treatments for many other rare conditions.